Prazosin, a central nervous system (CNS) active α-1 adrenoreceptor antagonist, has reduced nightmares and sleep disturbance in placebo-controlled studies of combat-related posttraumatic stress disorder (PTSD). We evaluated objective sleep parameters and PTSD symptoms in a placebo-controlled prazosin trial for civilian trauma-related PTSD.
Thirteen outpatients with chronic civilian trauma PTSD, frequent nightmares, and sleep disturbance participated in a randomized placebo-controlled crossover trial of prazosin. Sleep parameters were quantified at home with the REMView (Respironics, Pittsburgh, Pennsylvania). The PTSD symptoms were quantified with the Clinician Administered PTSD Scale (CAPS) “recurrent distressing dreams” and “disturbed sleep” items, a non-nightmare distressed awakenings scale, the PTSD Dream Rating Scale (PDRS), the PTSD Checklist-Civilian (PCL-C), and the Clinical Global Impression of Improvement (CGI-I).
Prazosin compared with placebo significantly increased total sleep time by 94 min; increased rapid eye movement (REM) sleep time and mean REM period duration without altering sleep onset latency; significantly reduced trauma-related nightmares, distressed awakenings, and total PCL scores; significantly improved CGI-I scores; and changed PDRS scores toward normal dreaming.
Prazosin reductions of nighttime PTSD symptoms in civilian trauma PTSD are accompanied by increased total sleep time, REM sleep time, and mean REM period duration in the absence of a sedative-like effect on sleep onset latency.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Biological Psychiatry
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Future pharmacotherapy for post-traumatic stress disorder: Prevention and treatment.Psychiatr Clin North Am. 2002; 25: 427-441
- Pharmacotherapy for disordered sleep in posttraumatic stress disorder: A systematic review.Int Clin Psychopharmacol. 2006; 21: 193-202
- Sleep disturbance as the hallmark of posttraumatic stress disorder.Am J Psychiatry. 1989; 146: 697-707
- Abnormal noradrenergic function in posttraumatic stress disorder.Arch Gen Psychiatry. 1993; 50: 266-274
- CSF norepinephrine concentrations in posttraumatic stress disorder.Am J Psychiatry. 2001; 158: 1227-1230
- Nocturnal/daytime urine noradrenergic measures and sleep in combat-related PTSD.Biol Psychiatry. 1995; 38: 174-179
- Activity patterns of catecholamine-containing pontine neurons in the dorso-lateral tegmentum of unrestrained cats.J Neurobiol. 1974; 5: 527-544
- Motor dysfunction during sleep in posttraumatic stress disorder.Sleep. 1994; 17: 723-732
- Sleep in lifetime posttraumatic stress disorder: a community-based polysomnographic study.Arch Gen Psychiatry. 2004; 61: 508-516
- Sleep events among veterans with combat-related posttraumatic stress disorder.Am J Psychiatry. 1995; 152: 110-115
- REM sleep and the early development of posttraumatic stress disorder.Am J Psychiatry. 2002; 159: 1696-1701
- Of sleep, memories and trauma.Nat Neurosci. 2007; 10: 540-542
- Prazosin selectively antagonizes neuronal responses mediated by alpha1-adrenoceptors in brain.Naunyn Schmiedebergs Arch Pharmacol. 1981; 317: 273-275
- Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: A placebo-controlled study.Am J Psychiatry. 2003; 160: 371-373
- The α1-adrenergic antagonist prazosin improves sleep and nightmares in civilian trauma posttraumatic stress disorder.J Clin Psychopharmacology. 2002; 22: 82-85
- A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbances in combat veterans with posttraumatic stress disorder.Biol Psychiatry. 2007; 61: 928-934
- Nightcap: Laboratory and home-based evaluation of a portable sleep monitor.Psychophysiology. 1995; 32: 92-98
- A pilot study of inexpensive sleep-assessment devices.Behav Sleep Med. 2004; 2: 41-49
- The PTSD Checklist: Reliability, validity, and diagnostic utility.1993 (Presented at the annual meeting of the International Society for Traumatic Stress Studies, San Antonio, Texas, October 24–27)
- The development of a clinician-administered PTSD scale.J Trauma Stress. 1995; 8: 75-80
- Physician’s Desk Reference.in: 55th ed. Medical Economics Company, Montvale, New Jersey2001: 2501-2502
- Design issues for the clinical evaluation of psychotropic drugs.in: Prien R.F. Robinson D.S. Clinical Evaluation of Psychotropic Drugs: Principles and Guidelines. Raven Press, New York1994: 29-68
- A comparison of severely distressed nocturnal awakenings with and without trauma-relevant nightmares in male veterans with combat PTSD and the efficacy of prazosin in reducing both: A chart review.2005 (Presented at the International Society for Traumatic Stress Studies Annual Scientific Meeting, November, Toronto, Canada.)
- Practicable and valid approach to evaluate the efficacy of nootropic drugs by means of rating scales.Pharmacopsychiatry. 1984; 17: 71-85
- Evaluation of dream content in combat-related PTSD.J Trauma Stress. 1999; 12: 681-687
- Interrater agreement and reliability measures of SAFTEE: General inquiry vs. systematic inquiry.Psychopharmacol Bull. 1987; 23: 97-101
- Effects of methoxamine, an alpha-1 adrenoreceptor agonist, and prazosin, an alpha-1 antagonist, on the stages of the sleep-waking cycle in the cat.Acta Physiol Scand. 1984; 120: 363-372
- Effects of methoxamine and alpha-adrenoceptor antagonists, prazosin and yohimbine, on the sleep-wake cycle of the rat.Sleep. 1984; 7: 365-372
- Modulation of desynchronized sleep through microinjection of alpha 1-adrenergic agonists and antagonists in the dorsal pontine tegmentum of the cat.Pflugers Arch. 1992; 422: 273-279
- REM sleep inhibition by desipramine: Evidence for an alpha-1 adrenergic mechanism.Brain Res. 1995; 701: 129-134
- Benzodiazepines and zolpidem for chronic insomnia: A meta-analysis of treatment efficacy.JAMA. 1997; 278: 2170-2177
- Cognitive behavior therapy and pharmacotherapy for insomnia.Arch Intern Med. 2004; 164: 1888-1896
Published online: September 17, 2007
Accepted: July 3, 2007
Received in revised form: June 19, 2007
Received: March 27, 2007
© 2008 Society of Biological Psychiatry. Published by Elsevier Inc. All rights reserved.